COMPANY PROFILE

Synklino

Strives to provide rapid relief and improve long-term survival for transplant recipients by providing fast and safe eradication of cytomegalovirus (CMV) infections

Copenhagen, DenmarkFounded 2017Biotech & Life Sciences

Valuation $100–250M Last recorded · 2022

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Synklino

Synklino is a biotechnology company focused on developing innovative treatments to eliminate cytomegalovirus (CMV) infections in transplant recipients. Operating in the healthcare and biotech market, Synklino serves patients who have undergone organ and stem cell transplants, providing them with a crucial safeguard against CMV, which can be devastating post-transplant. The company's business model revolves around the research, development, and commercialization of its proprietary treatments, generating revenue through the sale of these specialized medical solutions. By ensuring the elimination of CMV infections, Synklino helps patients recover faster and maintain their quality of life post-transplant.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2017
Headquarters: Copenhagen, Denmark
Employees: 14
Open positions: 1
Dealroom signal: 75.8/100
Industry: Health
Sub-industry: BioTechnology, Medical Devices
Sector: Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, Nordic Rising Star 2022, Hard Tech, Woman Founder, Horizon Europe, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

6 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
GRANTOther financing	Jul 2023	$332K	—	Horizon Europe	—
SERIES AOther financing	Jun 2022	$33M	$131M	Eir Ventures · PKA	↗

Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Growth signals

Synklino website traffic

Latest recorded traffic for Synklino is 120 monthly website visits, up 140% over the last three months. Synklino's team grew 7.7% over the past year.

Latest monthly visits120 3-month web change+140% 1-year team growth+7.7%

Monthly website visitsJan 2022–Jun 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
VTValo TherapeuticsAn immunooncology company developing tumour antigen-coated oncolytic viruses as therapeutic vaccines	Helsinki, Finland	Operational	11	$38M	$84M
ATAsgard TherapeuticsSpin-off company from Lund University focusing on developing cancer immunotherapies based on cell fate reprogramming	Lund Municipality, Sweden	Operational
MBMaxWell BiosystemsProvides next generation high-content electrophysiology platforms to facilitate detailed investigation of cells in vitro	Zurich, Switzerland	Operational
ATAtG TherapeuticsAt AtG, we develop novel classes of medicines and biomarkers to prevent cancer therapeutic resistance	L'Hospitalet de Llobregat, Spain	Operational
APAbarceo PharmaDeveloping small molecule technology platform for the treatment of mitochondrial dysfunction, with an initial focus on T2D	Malmö kommun, Sweden	Operational
PUPulmobioticsDiscovers and develops novel treatments and vaccines for respiratory diseases	Barcelona, Spain	Operational
MBMICA BiosystemsBiomagnetic technology for remote-controlled regenerative medicine applications	Solihull, United Kingdom	Operational
HPHcs PharmaA company specializing in cell imaging	Loos, France	Operational